

Company name: DAIICHI SANKYO COMPANY, LIMITED  
Representative: Joji Nakayama, Representative Director, President and CEO  
(Code no.: 4568, First Section, Tokyo Stock Exchange)  
Please address inquiries to Noriaki Ishida, Executive Officer,  
Vice President, Corporate Communications Department  
Telephone: +81-3-6225-1126  
<http://www.daiichisankyo.com>

**Revision to “Results Briefing (Results for Q1 FY2015)”**

**Tokyo, Japan (July 31, 2015)** – Daiichi Sankyo Company, Limited today announced a revision as follows to the “Results Briefing (Results for Q1 FY2015)” materials originally disclosed at 1:00pm on Thursday, July 31, 2015.

\*\*\*\*\*

Revised item

Page 11, Summary of revised revenue forecast: “FY2015 Original Forecast (May)” figures for Luitpold, Venofer and Injectafer (before and after revised figures are underlined below)

**Before**

	FY2015 Original Forecast (May)	FY2015 Revised Forecast (July)	Vs. Original Forecast
<b>Luitpold</b>	<u>125</u>	760	+40
Venofer	<u>72</u>	280	+10
Injectafer	<u>15</u>	170	+20

**After**

	FY2015 Original Forecast (May)	FY2015 Revised Forecast (July)	Vs. Original Forecast
<b>Luitpold</b>	<u>720</u>	760	+40
Venofer	<u>270</u>	280	+10
Injectafer	<u>150</u>	170	+20